Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome - 18/08/21
, Natalia V. Trushenko a, Svetlana Yu Chikina a, Natalia A. Tsareva a, Zamira M. Merzhoeva a, Andrey I. Yaroshetskiy a, Violetta I. Sopova b, Margarita I. Sopova b, Oleg A. Rosenberg c, Ralph Theo Schermuly d, Djuro Kosanovic a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
We have investigated the use of nebulized surfactant as a potential therapeutic option for the patients with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) undergoing non-invasive ventilation.
Methods |
The patients were divided into 2 groups: surfactant (n = 33) and control (n = 32). The subjects in the surfactant group received the inhaled surfactant at daily dose of 150–300 mg. The oxygenation parameters and several clinical outcomes were analyzed.
Results |
On the 5 day of therapy, PaO2/FiO2 improved significantly in the surfactant group compared to the control group (184 (155–212) mmHg vs 150 (91–173) mmHg, p = 0.02). The inhaled surfactant significantly reduced the need for transfer of patients to intensive care units (24.2% vs 46.9%, p = 0.05) and invasive mechanical ventilation (18.2% vs 40.6%, p = 0.04). Even more, the nebulized surfactant shortened the length of non-invasive ventilation (7 (3–13) days vs 11 (5–22) days, p = 0.02) and time spent in hospital (18 (16–27) days vs 26 (21–31) days, p = 0.003) in patients suffering from COVID-19-linked ARDS.
Conclusions |
Our preliminary data provided indications that inhaled surfactant therapy may represent a promising option for patients with COVID-19-associated ARDS. However, larger clinical trials are crucially needed.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Effects of nebulized surfactant were investigated in COVID-19 and ARDS patients. |
• | The application of inhaled surfactant improved the oxygenation parameters. |
• | It also had beneficial effects with regard to several clinical outcomes. |
• | Our data indicated that inhaled surfactant may be the promising therapeutic option. |
Keywords : Inhalation, Surfactant, COVID-19, Acute respiratory distress syndrome
Plan
Vol 185
Article 106489- août 2021 Retour au numéro
Article précédent
- Effects of non-invasive respiratory support on gas exchange and outcomes in COVID-19 outside the ICU
- Ciara Gough, Michelle Casey, Thomas A. McCartan, Alessandro N. Franciosi, Derek Nash, Dominic Doyle, Neil Hyland, Grace Kavanagh, Sile Toland, Caleb Powell, Rhea O'Regan, Ruán Ó. Conluain, Garrett Greene, Grace Murray, Israa Fathi Hussein, Eoin Hunt, Fatma Gargoum, David Curran, Tidi Hassan, Liam Cormican, Richard W. Costello, Tom McEnery
- Influence of vitamin D supplementation on the quality of life of asthma patients: Findings from ACVID randomised clinical trial
- R. Andújar-Espinosa, M. Aparicio-Vicente, F.J. Ruiz-López, L. Salinero-González
Bienvenue sur EM-consulte, la référence des professionnels de santé.